Predictive and prognostic biomarkers for neoadjuvant chemoradiotherapy in locally advanced rectal cancer

Critical Reviews in Oncology/Hematology

Volumn 96, Issue 1, 2015, Pages 67-80

  Lim, S H ^a,b,c   Chua, W ^a,b   Henderson, C ^a,c,d   Ng, W ^a,b   Shin, J S ^a,b,d   Chantrill, L ^e,f   Asghari, R ^g   Lee, C S ^a,b,d,h   Spring, K J ^b,c,d   de Souza, P ^a,b,c,d  

^a LIVERPOOL HOSPITAL   (Australia)

^b INGHAM INSTITUTE FOR APPLIED MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF WESTERN SYDNEY   (Australia)

^e Macarthur Cancer Therapy Centre   (Australia)

^f GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^g Department of Medical Oncology Bankstown Cancer Therapy Centre   (Australia)

^h UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Biomarker; Chemoradiation; Neoadjuvant; Rectal cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CIRCULATING TUMOR NUCLEIC ACID; CISPLATIN; CYTOKINE; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; MICRORNA; NUCLEIC ACID; OSTEOPONTIN; OXALIPLATIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UFT; UNCLASSIFIED DRUG; VASCULOTROPIN; TUMOR MARKER;

ADJUVANT CHEMORADIOTHERAPY; ADVANCED CANCER; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME ABERRATION; CIRCULATING TUMOR CELL; DRUG RESPONSE; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE MUTATION; HEMATOLOGICAL PARAMETERS; HUMAN; INFLAMMATION; INTRAOPERATIVE RADIOTHERAPY; MICROSATELLITE INSTABILITY; ONCOGENE K RAS; PREDICTION; RECTUM CANCER; RECTUM RESECTION; REVIEW; TIME TO TREATMENT; TREATMENT RESPONSE; TUMOR REGRESSION; CHEMORADIOTHERAPY; GENETICS; NEOADJUVANT THERAPY; PATHOLOGY; PROGNOSIS; RECTAL NEOPLASMS; TUMOR EMBOLISM;

BIOMARKERS, TUMOR; CHEMORADIOTHERAPY; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MICRORNAS; MICROSATELLITE INSTABILITY; NEOADJUVANT THERAPY; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; RECTAL NEOPLASMS;

EID: 84942200105     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.05.003     Document Type: Review

References (117)

1. Sauer R., Liersch T., Merkel S., Fietkau R., Hohenberger W., Hess C., et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012, 30(16):1926-1933.
2. Ngan S.Y., Burmeister B., Fisher R.J., Solomon M., Goldstein D., Joseph D., et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 2012, 30(31):3827-3833.
3. Bujko K., Nowacki M.P., Nasierowska-Guttmejer A., Michalski W., Bebenek M., Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006, 93(10):1215-1223.
4. Park I.J., You Y.N., Agarwal A., Skibber J.M., Rodriguez-Bigas M.A., Eng C., et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol 2012, 30(15):1770-1776.
5. Mohiuddin M., Hayne M., Regine W.F., Hanna N., Hagihara P.F., McGrath P., et al. Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. Int J Radiat Oncol Biol Phys 2000, 48(4):1075-1080.
6. Rodel C., Martus P., Papadoupolos T., Fuzesi L., Klimpfinger M., Fietkau R., et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005, 23(34):8688-8696.
7. Guillem J.G., Chessin D.B., Cohen A.M., Shia J., Mazumdar M., Enker W., et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg 2005, 241(5):829-836. discussion 836-8.
8. Fokas E., Liersch T., Fietkau R., Hohenberger W., Beissbarth T., Hess C., et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol 2014, 32(15):1554-1562.
9. Dworak O., Keilholz L., Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997, 12(1):19-23.
10. Mandard A.M., Dalibard F., Mandard J.C., Marnay J., Henry-Amar M., Petiot J.F., et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994, 73(11):2680-2686.
11. Ryan R., Gibbons D., Hyland J.M., Treanor D., White A., Mulcahy H.E., et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 2005, 47(2):141-146.
12. Rullier A., Laurent C., Capdepont M., Vendrely V., Bioulac-Sage P., Rullier E. Impact of tumor response on survival after radiochemotherapy in locally advanced rectal carcinoma. Am J Surg Pathol 2010, 34(4):562-568.
13. Edge S.B., Compton C.C. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010, 17(6):1471-1474.
14. Capirci C., Rampin L., Erba P.A., Galeotti F., Crepaldi G., Banti E., et al. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy. Eur J Nucl Med Mol Imaging 2007, 34(10):1583-1593.
15. Kim Y.H., Kim D.Y., Kim T.H., Jung K.H., Chang H.J., Jeong S.Y., et al. Usefulness of magnetic resonance volumetric evaluation in predicting response to preoperative concurrent chemoradiotherapy in patients with resectable rectal cancer. Int J Radiat Oncol Biol Phys 2005, 62(3):761-768.
16. Berger C., de Muret A., Garaud P., Chapet S., Bourlier P., Reynaud-Bougnoux A., et al. Preoperative radiotherapy (RT) for rectal cancer: predictive factors of tumor downstaging and residual tumor cell density (RTCD): prognostic implications. Int J Radiat Oncol Biol Phys 1997, 37(3):619-627.
17. Yan H., Wang R., Zhu K., Zhao W., Jiang S., Feng R., et al. Predictors of sensitivity to preoperative chemoradiotherapy of rectal adenocarcinoma. Tumori 2011, 97(6):717-723.
18. Das P., Skibber J.M., Rodriguez-Bigas M.A., Feig B.W., Chang G.J., Wolff R.A., et al. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer 2007, 109(9):1750-1755.
19. Garcia-Aguilar J., Smith D.D., Avila K., Bergsland E.K., Chu P., Krieg R.M., et al. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg 2011, 254(1):97-102.
20. Habr-Gama A., Perez R.O., Nadalin W., Sabbaga J., Ribeiro U., Silva e Sousa A.H., et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004, 240(4):711-717. discussion 717-8.
21. Gantt G.A., Chen Y., Dejulius K., Mace A.G., Barnholtz-Sloan J., Kalady M.F. Gene expression profile is associated with chemoradiation resistance in rectal cancer. Colorectal Dis 2014, 16(1):57-66.
22. Ramzan Z., Nassri A.B., Huerta S. Genotypic characteristics of resistant tumors to pre-operative ionizing radiation in rectal cancer. World J Gastrointest Oncol 2014, 6(7):194-210.
23. Spindler K.L., Nielsen J.N., Lindebjerg J., Brandslund I., Jakobsen A. Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region. Int J Radiat Oncol Biol Phys 2006, 66(2):500-504.
24. Stegeman H., Span P.N., Kaanders J.H., Bussink J. Improving chemoradiation efficacy by PI3-K/AKT inhibition. Cancer Treat Rev 2014, 40(10):1182-1191.
25. Glimelius B., Gronberg H., Jarhult J., Wallgren A., Cavallin-Stahl E. A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol 2003, 42(5/6):476-492.
26. Kuremsky J.G., Tepper J.E., McLeod H.L. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 2009, 74(3):673-688.
27. Spolverato G., Pucciarelli S., Bertorelle R., De Rossi A., Nitti D. Predictive factors of the response of rectal cancer to neoadjuvant radiochemotherapy. Cancers (Basel) 2011, 3(2):2176-2194.
28. Kikuchi M., Mikami T., Sato T., Tokuyama W., Araki K., Watanabe M., et al. High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction. Br J Cancer 2009, 101(1):116-123.
29. Smith F.M., Reynolds J.V., Miller N., Stephens R.B., Kennedy M.J. Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. Eur J Surg Oncol 2006, 32(1):55-64.
30. Kim K., Chie E.K., Wu H.G., Kim S.G., Lee S.H., Kang G.H., et al. High survivin expression as a predictor of poor response to preoperative chemoradiotherapy in locally advanced rectal cancer. Int J Colorectal Dis 2011, 26(8):1019-1023.
31. Chang H.J., Jung K.H., Kim D.Y., Jeong S.Y., Choi H.S., Kim Y.H., et al. Bax: a predictive marker for therapeutic response to preoperative chemoradiotherapy in patients with rectal carcinoma. Hum Pathol 2005, 36(4):364-371.
32. Yan H., Wang R., Yu J., Jiang S., Zhu K., Mu D., et al. Predictive value of Smac: VEGF and Ki-67 in rectal cancer treated with neoadjuvant therapy. Oncol Lett 2010, 1(4):641-647.
33. Stift A., Prager G., Selzer E., Widder J., Kandioler D., Friedl J., et al. The early response of p53-dependent proteins during radiotherapy in human rectal carcinoma and in adjacent normal tissue. Int J Oncol 2003, 23(5):1269-1275.
34. Marijnen C.A., Nagtegaal I.D., Mulder-Stapel A.A., Schrier P.I., van de Velde C.J., van Krieken J.H., et al. High intrinsic apoptosis: but not radiation-induced apoptosis, predicts better survival in rectal carcinoma patients. Int J Radiat Oncol Biol Phys 2003, 57(2):434-443.
35. Suzuki T., Sadahiro S., Fukasawa M., Ishikawa K., Kamijo A., Yasuda S., et al. Predictive factors of tumor shrinkage and histological regression in patients who received preoperative radiotherapy for rectal cancer. Jpn J Clin Oncol 2004, 34(12):740-746.
36. Debucquoy A., Goethals L., Geboes K., Roels S., Mc Bride W.H., Haustermans K. Molecular responses of rectal cancer to preoperative chemoradiation. Radiother Oncol 2006, 80(2):172-177.
37. Willett C.G., Warland G., Hagan M.P., Daly W.J., Coen J., Shellito P.C., et al. Tumor proliferation in rectal cancer following preoperative irradiation. J Clin Oncol 1995, 13(6):1417-1424.
38. Bertolini F., Bengala C., Losi L., Pagano M., Iachetta F., Dealis C., et al. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007, 68(5):1455-1461.
39. Debucquoy A., Libbrecht L., Roobrouck V., Goethals L., McBride W., Haustermans K. Morphological features and molecular markers in rectal cancer from 95 patients included in the European Organisation for Research and Treatment of Cancer 22921 trial: prognostic value and effects of preoperative radio (chemo) therapy. Eur J Cancer 2008, 44(6):791-797.
40. Zlobec I., Steele R., Nigam N., Compton C.C. A predictive model of rectal tumor response to preoperative radiotherapy using classification and regression tree methods. Clin Cancer Res 2005, 11(15):5440-5443.
41. Negri F.V., Campanini N., Camisa R., Pucci F., Bui S., Ceccon G., et al. Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. Br J Cancer 2008, 98(1):143-147.
42. Edler D., Glimelius B., Hallstrom M., Jakobsen A., Johnston P.G., Magnusson I., et al. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 2002, 20(7):1721-1728.
43. Suzuki T., Sadahiro S., Tanaka A., Okada K., Kamata H., Kamijo A., et al. Biopsy specimens obtained 7 days after starting chemoradiotherapy (CRT) provide reliable predictors of response to CRT for rectal cancer. Int J Radiat Oncol Biol Phys 2013, 85(5):1232-1238.
44. Dalerba P., Dylla S.J., Park I.K., Liu R., Wang X., Cho R.W., et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007, 104(24):10158-10163.
45. Jordan C.T., Guzman M.L., Noble M. Cancer stem cells. N Engl J Med 2006, 355(12):1253-1261.
46. Huh J.W., Lee J.H., Kim H.R. Pretreatment expression of 13 molecular markers as a predictor of tumor responses after neoadjuvant chemoradiation in rectal cancer. Ann Surg 2014, 259(3 (Mar)):508-515.
47. Saigusa S., Tanaka K., Toiyama Y., Yokoe T., Okugawa Y., Koike Y., et al. Clinical significance of CD133 and hypoxia inducible factor-1alpha gene expression in rectal cancer after preoperative chemoradiotherapy. Clin Oncol (R Coll Radiol) 2011, 23(5):323-332.
48. Zhang S.S., Han Z.P., Jing Y.Y., Tao S.F., Li T.J., Wang H., et al. CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients. BMC Med 2012, 10:85.
49. Nieto M.A., Cano A. The epithelial-mesenchymal transition under control: global programs to regulate epithelial plasticity. Semin Cancer Biol 2012, 22(5/6):361-368.
50. Dienstmann R., Guinney J., Delorenzi M., De Reynies A., Roepman P., Sadanandam A. Colorectal cancer subtyping consortium (CRCSC) identification of a consensus of molecular subtypes. J Clin Oncol 2014, 32(5s). p. suppl; abstr 3511.
51. Bhangu A., Wood G., Brown G., Darzi A., Tekkis P., Goldin R. The role of epithelial mesenchymal transition and resistance to neoadjuvant therapy in locally advanced rectal cancer. Colorectal Dis 2014, 16(4):O133-O143.
52. Ishikubo T., Nishimura Y., Yamaguchi K., Khansuwan U., Arai Y., Kobayashi T., et al. The clinical features of rectal cancers with high-frequency microsatellite instability (MSI-H) in Japanese males. Cancer Lett 2004, 216(1):55-62.
53. Shin J.S., Tut T.G., Yang T., Lee C.S. Radiotherapy response in microsatellite instability related rectal cancer. Korean J Pathol 2013, 47(1):1-8.
54. Roepman P., Schlicker A., Tabernero J., Majewski I., Tian S., Moreno V., et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit: deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer 2014, 134(3):552-562.
55. Charara M., Edmonston T.B., Burkholder S., Walters R., Anne P., Mitchell E., et al. Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy. Anticancer Res 2004, 24(5B):3161-3167.
56. Demes M., Scheil-Bertram S., Bartsch H., Fisseler-Eckhoff A. Signature of microsatellite instability: KRAS and BRAF gene mutations in German patients with locally advanced rectal adenocarcinoma before and after neoadjuvant 5-FU radiochemotherapy. J Gastrointest Oncol 2013, 4(2):182-192.
57. Franchitto A., Pichierri P., Piergentili R., Crescenzi M., Bignami M., Palitti F. The mammalian mismatch repair protein MSH2 is required for correct MRE11 and RAD51 relocalization and for efficient cell cycle arrest induced by ionizing radiation in G2 phase. Oncogene 2003, 22(14):2110-2120.
58. Park Y.A., Sohn S.K., Seong J., Baik S.H., Lee K.Y., Kim N.K., et al. Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer. J Surg Oncol 2006, 93(2):145-150.
59. Moureau-Zabotto L., Farnault B., de Chaisemartin C., Esterni B., Lelong B., Viret F., et al. Predictive factors of tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2011, 80(2):483-491.
60. Tural D., Selcukbiricik F., Dztfcrk M.A., Yildiz D., Turna H., Erdamar S., et al. The relation between pathologic complete response and clinical outcome in patients with rectal cancer. Hepatogastroenterology 2013, 60(128).
61. Sorensen N.M., Bystrom P., Christensen I.J., Berglund A., Nielsen H.J., Brunner N., et al. TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan: 5-fluorouracil, and folinic acid. Clin Cancer Res 2007, 13(14):4117-4122.
62. Aldulaymi B., Christensen I.J., Soletormos G., Jess P., Nielsen S.E., Laurberg S., et al. Chemoradiation-induced changes in serum CEA and plasma TIMP-1 in patients with locally advanced rectal cancer. Anticancer Res 2010, 30(11):4755-4759.
63. Yoon H.I., Koom W.S., Kim Y.B., Min B.S., Lee K.Y., Kim N.K., et al. Predicting the pathologic response of locally advanced rectal cancer to neoadjuvant concurrent chemoradiation using enzyme-linked immunosorbent assays (ELISAs) for biomarkers. J Cancer Res Clin Oncol 2014, 140(3):399-409.
64. Yasuda K., Sunami E., Kawai K., Nagawa H., Kitayama J. Laboratory blood data have a significant impact on tumor response and outcome in preoperative chemoradiotherapy for advanced rectal cancer. J Gastrointest Cancer 2012, 43(2):236-243.
65. Dou X., Wang R.B., Yan H.J., Jiang S.M., Meng X.J., Zhu K.L., et al. Circulating lymphocytes as predictors of sensitivity to preoperative chemoradiotherapy in rectal cancer cases. Asian Pac J Cancer Prev 2013, 14(6):3881-3885.
66. Kitayama J., Yasuda K., Kawai K., Sunami E., Nagawa H. Circulating lymphocyte is an important determinant of the effectiveness of preoperative radiotherapy in advanced rectal cancer. BMC Cancer 2011, 11:64.
67. Palma P., Cuadros M., Conde-Muino R., Olmedo C., Cano C., Segura-Jimenez I., et al. Microarray profiling of mononuclear peripheral blood cells identifies novel candidate genes related to chemoradiation response in rectal cancer. PLOS ONE 2013, 8(9):e74034.
68. Galon J., Mlecnik B., Bindea G., Angell H.K., Berger A., Lagorce C., et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol 2014, 232(2):199-209.
69. Galon J., Pages F., Marincola F.M., Angell H.K., Thurin M., Lugli A., et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012, 10:205.
70. Buijsen J., van Stiphout R.G., Menheere P.P., Lammering G., Lambin P. Blood biomarkers are helpful in the prediction of response to chemoradiation in rectal cancer: A prospective, hypothesis driven study on patients with locally advanced rectal cancer 2014, Radiother Oncol.
71. Slattery M.L., Wolff R.K., Herrick J.S., Caan B.J., Potter J.D. IL6 genotypes and colon and rectal cancer. Cancer Causes Control 2007, 18(10):1095-1105.
72. Inoue Y., Ojima E., Watanabe H., Hiro J., Toiyama Y., Kobayashi M., et al. Does preoperative chemo-radiotherapy enhance the expression of vascular endothelial growth factor in patients with rectal cancer?. Oncol Rep 2007, 18(2):369-375.
73. Motoyama K., Inoue H., Takatsuno Y., Tanaka F., Mimori K., Uetake H., et al. Over- and under-expressed microRNAs in human colorectal cancer. Int J Oncol 2009, 34(4):1069-1075.
74. Gaedcke J., Grade M., Camps J., Sokilde R., Kaczkowski B., Schetter A.J., et al. The rectal cancer microRNAome - microRNA expression in rectal cancer and matched normal mucosa. Clin Cancer Res 2012, 18(18):4919-4930.
75. Li X., Zhang G., Luo F., Ruan J., Huang D., Feng D., et al. Identification of aberrantly expressed miRNAs in rectal cancer. Oncol Rep 2012, 28(1):77-84.
76. Arndt G.M., Dossey L., Cullen L.M., Lai A., Druker R., Eisbacher M., et al. Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer 2009, 9:374.
77. Ng E.K., Chong W.W., Jin H., Lam E.K., Shin V.Y., Yu J., et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009, 58(10):1375-1381.
78. Michael M.Z., O'Connor S.M., van Holst Pellekaan N.G., Young G.P., James R.J. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003, 1(12):882-891.
79. Lopes-Ramos C., Habr-Gama A., Quevedo B., Felicio N., Bettoni F., Koyama F., et al. Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients. BMC Med Genomics 2014, 7(1):68.
80. Salendo J., Spitzner M., Kramer F., Zhang X., Jo P., Wolff H.A., et al. Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells: involving miRNAs-320a, -224, -132 and let7g. Radiother Oncol 2013, 108(3):451-457.
81. Valeri N., Braconi C., Gasparini P., Murgia C., Lampis A., Paulus-Hock V., et al. MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. Cancer Cell 2014, 25(4):469-483.
82. McDermott A.M., Heneghan H.M., Miller N., Kerin M.J. The therapeutic potential of microRNAs: disease modulators and drug targets. Pharm Res 2011, 28(12):3016-3029.
83. Garcia-Aguilar J., Chen Z., Smith D.D., Li W., Madoff R.D., Cataldo P., et al. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer. Ann Surg 2011, 254(3):486-492. discussion 492-3.
84. Ghadimi B.M., Grade M., Difilippantonio M.J., Varma S., Simon R., Montagna C., et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 2005, 23(9):1826-1838.
85. Nishioka M.S.M., Kurita N., Iwata T., Morimoto S., Yoshikawa K., Higashijima J., Miyatani T. Gene expression profile can predict pathological response to preoperative chemoradiotherapy in rectal cancer. Cancer Genomics Proteomics 2011, 8:87-92.
86. Kim I.J., Lim S.B., Kang H.C., Chang H.J., Ahn S.A., Park H.W., et al. Microarray gene expression profiling for predicting complete response to preoperative chemoradiotherapy in patients with advanced rectal cancer. Dis Colon Rectum 2007, 50(9):1342-1353.
87. Watanabe T., Komuro Y., Kiyomatsu T., Kanazawa T., Kazama Y., Tanaka J., et al. Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. Cancer Res 2006, 66(7):3370-3374.
88. Chen Z., Liu Z., Li W., Qu K., Deng X., Varma M.G., et al. Chromosomal copy number alterations are associated with tumor response to chemoradiation in locally advanced rectal cancer. Genes Chromosomes Cancer 2011, 50(9):689-699.
89. Luna-Perez P., Segura J., Alvarado I., Labastida S., Santiago-Payan H., Quintero A. Specific c-K-ras gene mutations as a tumor-response marker in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Ann Surg Oncol 2000, 7(10):727-731.
90. Gaedcke J., Grade M., Jung K., Schirmer M., Jo P., Obermeyer C., et al. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. Radiother Oncol 2010, 94(1):76-81.
91. Zauber N.P., Marotta S.P., Berman E., Grann A., Rao M., Komati N., et al. Molecular genetic changes associated with colorectal carcinogenesis are not prognostic for tumor regression following preoperative chemoradiation of rectal carcinoma. Int J Radiat Oncol Biol Phys 2009, 74(2):472-476.
92. Schwarzenbach H., Hoon D.S., Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011, 11(6):426-437.
93. Pucciarelli S., Rampazzo E., Briarava M., Maretto I., Agostini M., Digito M., et al. Telomere-specific reverse transcriptase (hTERT) and cell-free RNA in plasma as predictors of pathologic tumor response in rectal cancer patients receiving neoadjuvant chemoradiotherapy. Ann Surg Oncol 2012, 19(9):3089-3096.
94. Zitt M., Muller H.M., Dinnewitzer A.J., Schwendinger V., Goebel G., De Vries A., et al. Disseminated tumor cells in peripheral blood: a novel marker for therapy response in locally advanced rectal cancer patients undergoing preoperative chemoradiation. Dis Colon Rectum 2006, 49(10):1484-1491.
95. Kienle P., Koch M., Autschbach F., Benner A., Treiber M., Wannenmacher M., et al. Decreased detection rate of disseminated tumor cells of rectal cancer patients after preoperative chemoradiation: a first step towards a molecular surrogate marker for neoadjuvant treatment in colorectal cancer. Ann Surg 2003, 238(3):324-330. discussion 330-1.
96. Zitt M., Muller H.M., Rochel M., Schwendinger V., Goebel G., Devries A., et al. Circulating cell-free DNA in plasma of locally advanced rectal cancer patients undergoing preoperative chemoradiation: a potential diagnostic tool for therapy monitoring. Dis Markers 2008, 25(3):159-165.
97. Lim S.H., Becker T.M., Chua W., Caixeiro N.J., Ng W.L., Kienzle N., et al. Circulating tumour cells and circulating free nucleic acid as prognostic and predictive biomarkers in colorectal cancer. Cancer Lett 2014, 346(1):24-33.
98. Caixeiro N.J., Kienzle N., Lim S.H., Spring K.J., Tognela A., Scott K.F., et al. Circulating tumour cells-a bona fide cause of metastatic cancer. Cancer Metastasis Rev 2014.
99. Galizia G., Gemei M., Orditura M., Romano C., Zamboli A., Castellano P., et al. Postoperative detection of circulating tumor cells predicts tumor recurrence in colorectal cancer patients. J Gastrointest Surg 2013, 17(10):1809-1818.
100. Lim S.H., Becker T.M., Chua W., Ng W.L., de Souza P., Spring K.J. Circulating tumour cells and the epithelial mesenchymal transition in colorectal cancer 2014, J Clin Pathol.
101. Park H.C., Janjan N.A., Mendoza T.R., Lin E.H., Vadhan-Raj S., Hundal M., et al. Temporal patterns of fatigue predict pathologic response in patients treated with preoperative chemoradiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys 2009, 75(3):775-781.
102. Ballian N., Yamane B., Leverson G., Harms B., Heise C.P., Foley E.F., et al. Body mass index does not affect postoperative morbidity and oncologic outcomes of total mesorectal excision for rectal adenocarcinoma. Ann Surg Oncol 2010, 17(6):1606-1613.
103. Clark W., Siegel E.M., Chen Y.A., Zhao X., Parsons C.M., Hernandez J.M., et al. Quantitative measures of visceral adiposity and body mass index in predicting rectal cancer outcomes after neoadjuvant chemoradiation. J Am Coll Surg 2013, 216(6):1070-1081.
104. Milgrom S., Garcia-Aguilar J. Molecular biomarkers as predictors of response to neoadjuvant chemoradiation therapy in rectal cancer. Sem Colon Rectal Surg 2013, 24:119-124.
105. Debucquoy A., Goethals L., Libbrecht L., Perneel C., Geboes K., Ectors N., et al. Molecular and clinico-pathological markers in rectal cancer: a tissue micro-array study. Int J Colorectal Dis 2009, 24(2):129-138.
106. Szelachowska J., Dziegiel P., Tarkowski R., Gomulkiewicz A., Bebenek M., Halon A., et al. Therapeutic radiation induces different changes in expression profiles of metallothionein (MT) mRNA: MT protein, Ki 67 and minichromosome maintenance protein 3 in human rectal adenocarcinoma. Anticancer Res 2012, 32(12):5291-5297.
107. Smith F.M., Reynolds J.V., Kay E.W., Crotty P., Murphy J.O., Hollywood D., et al. COX-2 overexpression in pretreatment biopsies predicts response of rectal cancers to neoadjuvant radiochemotherapy. Int J Radiat Oncol Biol Phys 2006, 64(2):466-472.
108. Rodel F., Keppner S., Capalbo G., Bashary R., Kaufmann M., Rodel C., et al. Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer. Am J Pathol 2010, 177(2):918-929.
109. Lee-Kong S.A., Ruby J.A., Chessin D.B., Pucciarelli S., Shia J., Riedel E.R., et al. Hypoxia-related proteins in patients with rectal cancer undergoing neoadjuvant combined modality therapy. Dis Colon Rectum 2012, 55(9):990-995.
110. Korkeila E., Talvinen K., Jaakkola P.M., Minn H., Syrjanen K., Sundstrom J., et al. Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer. Br J Cancer 2009, 100(6):874-880.
111. Toiyama Y., Inoue Y., Saigusa S., Okugawa Y., Yokoe T., Tanaka K., et al. Gene expression profiles of epidermal growth factor receptor: vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery. Clin Oncol (R Coll Radiol) 2010, 22(4):272-280.
112. Guedj N., Bretagnol F., Rautou P.E., Deschamps L., Cazals-Hatem D., Bedossa P., et al. Predictors of tumor response after preoperative chemoradiotherapy for rectal adenocarcinomas. Hum Pathol 2011, 42(11):1702-1709.
113. Della Vittoria Scarpati G., Falcetta F., Carlomagno C., Ubezio P., Marchini S., De Stefano A., et al. A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2012, 83(4):1113-1119.
114. Kheirelseid E.A., Miller N., Chang K.H., Curran C., Hennessey E., Sheehan M., et al. miRNA expressions in rectal cancer as predictors of response to neoadjuvant chemoradiation therapy. Int J Colorectal Dis 2013, 28(2):247-260.
115. Svoboda M., Sana J., Fabian P., Kocakova I., Gombosova J., Nekvindova J., et al. MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Radiat Oncol 2012, 7:195.
116. Eva Bandres A., Guerrero D., Lopez I., Gonzalez-Huarriz M., Gomez Dorronsoro M.L., Montes M., Monzon F., Torrea N., Armendariz P., Balen E., Viudez A., Asin G., Chicata V., Hernandez I., Eito C., Garcia-Foncillas J. Association between a specific miRNA signature and pathological response to neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer (LARC) patients. ASCO 2012.
117. Drebber U., Lay M., Wedemeyer I., Vallbohmer D., Bollschweiler E., Brabender J., et al. Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy. Int J Oncol 2011, 39(2):409-415.